Caroline J. Springer

13.5k citations

127 papers · 8.9k indexed · 2 hit papers · h-index 44

Molecular Biology top 0.5%
Oncology top 0.5%
Genetics top 1%
Organic Chemistry top 2%
Computational Theory and Mathematics top 0.5%

Co-authors: Richard Marais Dan Niculescu‐Duvaz Ion Niculescu‐Duvaz Christopher J. Marshall David Barford Mathew J. Garnett Paul Wan Chris M. Jones
Topics: Virus-based gene therapy research (43 papers)Cancer Research and Treatments (38 papers)Monoclonal and Polyclonal Antibodies Research (28 papers)
Cited by: Oncology Biotechnology Molecular Biology
Journals: Cell Journal of Clinical Investigation Nature Communications
Partner nations: United Kingdom United States Canada

In The Last Decade

Caroline J. Springer

126 papers receiving 8.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

2004 2.2k citations Dan Niculescu‐Duvaz, Christopher J. Marshall et al. profile →
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

2010 1.1k citations Steven R. Whittaker, Nathalie Dhomen et al. profile →

Peers

Countries citing papers authored by Caroline J. Springer

Since Specialization

Citations

This map shows the geographic impact of Caroline J. Springer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline J. Springer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline J. Springer more than expected).

Fields of papers citing papers by Caroline J. Springer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline J. Springer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline J. Springer. The network helps show where Caroline J. Springer may publish in the future.

Co-authorship network of co-authors of Caroline J. Springer

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline J. Springer. A scholar is included among the top collaborators of Caroline J. Springer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline J. Springer. Caroline J. Springer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography 2019 ·Cancer Research ·Jin Li,(unknown),Jessica K.R. Boult,(unknown),Andreas Heindl,(unknown),(unknown),Craig Cummings,Caroline J. Springer,Louis Chesler,Chris Jones,Jeffrey C. Bamber,Yinyin Yuan,Ralph Sinkus,Yann Jamin,Simon P. Robinson	43
2	Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface 2017 ·Nature Communications ·Haoran Tang,(unknown),Grazia Saturno,Amaya Virós,Duncan L. Smith,Gianpiero Di Leva,(unknown),Dan Niculescu‐Duvaz,Filipa M. Lopes,Louise D. Johnson,Nathalie Dhomen,Caroline J. Springer,Richard Marais	73
3	Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma 2015 ·Molecular Cancer Therapeutics ·Victoria L. Bridgeman,Elaine Y. Wan,Shane Foo,Mark R. Nathan,Jonathan Welti,Sophia Frentzas,Peter Vermeulen,Natasha Preece,Caroline J. Springer,Thomas Powles,Paul Nathan,James Larkin,Martin Gore,Naveen Vasudev,Andrew R. Reynolds	38
4	Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes 2013 ·Cancer Discovery ·Malin Pedersen,Heidi V.N. Küsters‐Vandevelde,Amaya Virós,Patricia J.T.A. Groenen,Berta Sanchez‐Laorden,(unknown),(unknown),W.O. Renier,Jolanda Schieving,Ion Niculescu‐Duvaz,Caroline J. Springer,Benno Küsters,Pieter Wesseling,Willeke A.M. Blokx,Richard Marais	51
5	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma 2012 ·Cancer Discovery ·María Romina Girotti,Malin Pedersen,Berta Sanchez‐Laorden,Amaya Virós,Samra Turajlic,Dan Niculescu‐Duvaz,Alfonso Zambon,John Sinclair,Andrew Hayes,Martin Gore,Paul Lorigan,Caroline J. Springer,James Larkin,Claus Jørgensen,Richard Marais	272
6	Contrasting effects of sunitinib within in vivo models of metastasis 2012 ·Angiogenesis ·Jonathan Welti,Thomas Powles,Shane Foo,Morgane Gourlaouen,Natasha Preece,Julie Foster,Sophia Frentzas,D. K. Bird,Kevin Sharpe,Antoinette van Weverwijk,David Robertson,(unknown),Janine T. Erler,Роберто Пили,Caroline J. Springer,Stephen J. Mather,Andrew R. Reynolds	58
7	A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF 2010 ·Cancer Research ·Steven R. Whittaker,Delphine Ménard,Richard Kirk,Lesley Ogilvie,Douglas Hedley,Alfonso Zambon,Filipa M. Lopes,Natasha Preece,(unknown),Sareena Rana,Maryou Lambros,Jorge S. Reis‐Filho,Richard Marais,Caroline J. Springer	15
8	Evidence of efficacy of antibody directed enzyme prodrug therapy (ADEPT) in a Phase I trial in patients with advanced carcinoma. 2008 ·Cancer Research ·(unknown),Astrid Mayer,Surinder K. Sharma,Berend Tolner,Roslyn J. Francis,Caroline J. Springer,(unknown),G Boxer,James R. Bell,Alan Green,(unknown),(unknown),(unknown),(unknown),Kerry Chester,Richard H. J. Beǵent	2
9	In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling 2006 ·Cancer Research ·Nicolas Dumaz,Robert Hayward,Jan Martin,Lesley Ogilvie,Douglas Hedley,John A. Curtin,Boris C. Bastian,Caroline J. Springer,Richard Marais	241
10	Suicide gene therapy : methods and reviews 2004 ·Caroline J. Springer	11
11	Introduction to Vectors for Suicide Gene Therapy 2004 ·Humana Press eBooks ·Caroline J. Springer	3
12	Design of Prodrugs for Suicide Gene Therapy 2004 ·Humana Press eBooks ·Dan Niculescu‐Duvaz,Ion Niculescu‐Duvaz,Caroline J. Springer	13
13	B-RAF is a therapeutic target in melanoma 2004 ·Oncogene ·Maria Karasarides,Antonio Chiloeches,Robert Hayward,Dan Niculescu‐Duvaz,Ian Scanlon,Frank Friedlos,Lesley Ogilvie,Douglas Hedley,Jan Martin,Christopher J. Marshall,Caroline J. Springer,Richard Marais	360
14	Prodrug-activating systems in suicide gene therapy 2000 ·Journal of Clinical Investigation ·Caroline J. Springer,Ion Niculescu‐Duvaz	166
15	Virus-directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954 1998 ·British Journal of Cancer ·Iain A. McNeish,(unknown),(unknown),Stephen M. Roberts,Rachel Kerr,Frank Friedlos,Caroline J. Springer,Peter F. Searle	2
16	Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase 1998 ·Gene Therapy ·Frank Friedlos,(unknown),(unknown),(unknown),Caroline J. Springer	51
17	The Bystander Effect of the Nitroreductase/CB 1954 Enzyme/Prodrug System Is Due to a Cell-Permeable Metabolite 1997 ·Human Gene Therapy ·John Bridgewater,R.J. Knox,J. D. Pitts,Mary Collins,Caroline J. Springer	108
18	Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. 1994 ·PubMed ·Sue Eccles,William Court,(unknown),Christopher Dean,RG Melton,Caroline J. Springer	56
19	Antitumor effects of an antibody-carboxypeptidase g2 conjugate in combination with a benzoic acid mustard prodrug 1993 ·Cell Biophysics ·D C Blakey,B. Valcaccia,(unknown),(unknown),(unknown),Caroline J. Springer,Philip J. Burke,Roger G. Melton,K. D. Bagshawe	16
20	Postprandial Gastrin Concentrations Are Higher in Female Patients with Duodenal Ulcers 1989 ·Digestion ·J Calam,Caroline J. Springer,(unknown),(unknown)	1

About Caroline J. Springer

Caroline J. Springer is a scholar working on Biotechnology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 127 papers that have together received 8.9k indexed citations. Recurring topics across this work include Virus-based gene therapy research (43 papers), Cancer Research and Treatments (38 papers) and Monoclonal and Polyclonal Antibodies Research (28 papers). The work is most often cited by research in Oncology (3.1k citations), Biotechnology (895 citations) and Molecular Biology (6.6k citations). Caroline J. Springer has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Richard Marais, Dan Niculescu‐Duvaz, Ion Niculescu‐Duvaz, Christopher J. Marshall, David Barford, Mathew J. Garnett, Paul Wan, Chris M. Jones, S. Mark Roe and Valerie M. Good. Their work appears in journals such as Cell, Journal of Clinical Investigation and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact